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http://dxObjectives:Membrane type 1 matrix metalloproteinase (MT1-MMP) is critical to a number of proteolytic and
profibrotic events. However, upstream regulation of MT1-MMP with myocardial ischemia–reperfusion remains
poorly understood. MicroRNAs regulate post-transcriptional events, and in silico mapping has identified a con-
served sequence in MT1-MMP for microRNA-133a. This study tested the hypothesis that changes in
microRNA-133a regulation occur with myocardial ischemia–reperfusion, which contributes to time- and
region-dependent changes in MT1-MMP activity and processing of MT1-MMP substrates.
Methods: Yorkshire pigs (n ¼ 12) underwent ischemia–reperfusion (90 minutes ischemia and 120 minutes
reperfusion), where regional preload recruitable stroke work (sonomicrometry), interstitial MT1-MMP activity
(microdialysis), Smad2 abundance (immunoblotting), and interstitial microRNA-133a (polymerase chain reac-
tion) were determined within the ischemia–reperfusion and remote regions. Human left ventricular fibroblasts
were transduced with microRNA-133a and anti–microRNA-133a (lentivirus) to determine the effects on
MT1-MMP protein abundance.
Results: With ischemia–reperfusion, regional preload recruitable stroke work decreased from steady state
(139  20 mm Hg to 44  11 mm Hg, P<.05) within the ischemia–reperfusion region. MT1-MMP activity
increased in both regions. Phosphorylated Smad2 increased within the ischemia–reperfusion region. Both
in vitro and in vivo interstitial levels of microRNA-133a decreased with ischemia and returned to steady-
state levels with reperfusion. In vitro transduction of microRNA-133a in left ventricular fibroblasts decreased
MT1-MMP levels.
Conclusions: Modulation of MT1-MMP activity and microRNA-133a exportation into the myocardial interstitium
occurred in the setting of acutemyocardial ischemia–reperfusion. In addition, changes inmicroRNA-133a expression
in left ventricular fibroblasts resulted in an inverse modulation of MT1-MMP abundance. Therefore, targeting of
microRNA-133a represents a potentially novel means for regulating the cascade of profibrotic events after ische-
mia–reperfusion. (J Thorac Cardiovasc Surg 2013;145:267-77)Supplemental material is available online.e Division of Cardiothoracic Surgery,a Medical University of South Carolina,
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SRestoration of blood flow, or reperfusion, after myocardial
ischemia can trigger a number of biological responses, in-
cluding induction of the matrix metalloproteinases
(MMPs), which can culminate in ischemia–reperfusion
(I/R) injury and myocardial dysfunction.1-3 One particular
MMP, membrane type 1 MMP (MT1-MMP), has been im-
plicated in remodeling of the extracellular matrix (ECM)
and is up-regulated in animal models of I/R.1-6 However,
upstream regulation of MT1-MMP remains unknown. The
microRNAs (miRs) play a role in regulating MT1-MMP
expression by inhibiting translation or stimulating mRNA
degradation.7 For example, changes in myocardial
miR-29a levels were associated with ECM remodeling in
the setting of I/R.8 Furthermore, changes inmiR-133a levels
were associated with modulation of ECM collagen.9,10With
the use of in silico mapping studies, a putative miR-133a
binding site in the MT1-MMP transcript and in the tran-
scripts of other members of the transforming growth
factor-beta (TGF-b) pathway was identified.11-13 Inrdiovascular Surgery c Volume 145, Number 1 267
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
ECM ¼ extracellular matrix
FGM ¼ fibroblast growth medium
I/R ¼ ischemia–reperfusion
LTBP-1 ¼ latent transforming growth factor
binding protein 1
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PCR ¼ polymerase chain reaction
pSmad2 ¼ phosphorylated Smad2
rPRSW ¼ regional preload recruitable stroke
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through proteolysis of latent transforming growth factor
binding protein 1 (LTBP-1).2,3,14 LTBP-1 proteolysis re-
leases TGF-b, which promotes phosphorylation of Smads
(Smad2) and downstream transcription of type I colla-
gen.15,16 However, whether activation of TGF-b signaling
cascade occurs with acute myocardial I/R injury has not
been established. Therefore, this study tested the
hypothesis that changes in miR-133a expression/abundance
occur with acute myocardial I/R, coincident with time- and
region-dependent changes in MT1-MMP substrate process-
ing and activation of profibrotic pathways.MATERIALS AND METHODS
Model of Ischemia–Reperfusion
Yorkshire pigs (n¼ 12, 30 to 35 kg; Hambone Farms, Orangeburg, SC)
were instrumented for transient coronary artery occlusion.1,2 Briefly, a pair
of sonomicrometry crystals and microdialysis probes were placed within
the I/R region (posterior left ventricular [LV] wall) and in a defined
remote region (anterior apical LV). Regional preload recruitable stroke
work (rPRSW) was determined.1 After steady state, ischemia was induced
for 90 minutes and then released for 120 minutes of reperfusion, and
rPRSW was measured at 30-minute intervals. After the I/R protocol, the
LV free wall was harvested for biochemical analysis. Pigs with no I/R
(n¼ 5) were included as referent controls. Animals were treated and cared
for in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (National Institutes of Health, 1996). Ad-
ditional information is provided in the Online Supplemental Methods.
Microdialysis and Fluorogenic Substrate
Measurements
Microdialysis probes (20 kDa; CMA/Microdialysis, North Chelmsford,
Mass) were placed in the mid-myocardium, and quenched fluorogenic pep-
tides containing an artificial MT1-MMP-specific hydrolysis site or an268 The Journal of Thoracic and Cardiovascular Surgendogenous MT1-MMP hydrolysis site from LTBP-1 were infused (3
mL/min) as previously described.1,3,17,18 Interstitial MT1-MMP activity
or LTBP-1 hydrolysis was determined as a function of the fluorescence
in the dialysate.
Immunoblotting
Immunoblotting was performed to determine myocardial levels of phos-
phorylated Smad2 (pSmad2) and Smad2 (antibodies 3101 and 5339, re-
spectively; Cell Signaling, Danvers, Mass) and MT1-MMP (AB8221;
Millipore, Billerica, Mass).1 The immunoreactive signals were analyzed
using densitometric methods.
mRNA Quantification
Myocardial mRNA levels were determined using real-time polymerase
chain reaction (PCR). Primer/probe sets were synthesized for porcine
LTBP-1 and TGF-b receptor 1 (TGF-bR1), and purchased for MT1-
MMP, MMP-9, type I collagen, and 18S rRNA (cat. no. Ss0339441_ml,
Ss03392098_m1, Ss03373340_m1, and Hs99999901_s1, respectively; Ap-
plied Biosystems, Foster City, Calif).
Bioinformatics Analysis of microRNA-133a
In silico mapping of the 30 untranslated region (UTR) of the human
MT1-MMP gene (TargetScan Human 5.1, www.targetscan.org) identified
a high-probability target for miR-133a (context score 0.17, PCt
0.34).11-13,19 Of note, the 8-mer seed sequence was perfectly replicated
in the 30-UTR of the porcine MT1-MMP gene. Moreover, when the human
and porcine 30-UTRs of MT1-MMP are aligned (ClustalW2; http://www.
ebi.ac.uk/Tools/msa/ clustalw2/), the miR-133a target nucleotide sequence
matches with identity at 25 of 31 base pairs, suggesting that porcine MT1-
MMPs also possess a high-fidelity target site for miR-133a. In similar fash-
ion, miR-133a putatively targets several other genes that play an important
role in the profibrotic response, includingMMP-9, LTBP-1, TGF-bR1, and
type I collagen.9,10,13
microRNA Quantification
miR levels were determined in myocardial homogenates, microdialy-
sate samples, and conditioned media samples (100 mL) from the in vitro
studies. Isolated RNA was reverse transcribed, and expression levels of
miR-133a and miR-29a were determined.
Simulated Ischemia–Reperfusion in Porcine Left
Ventricular Fibroblasts
Porcine LV fibroblasts were incubated for 120 minutes in normoxic me-
dium (O2 tension>250 Torr).
20 The dishes were then incubated in hypoxic
medium (2 mL), which was infused with 95% nitrogen, 5% CO2 for 30
minutes (O2 tension<50 Torr). Next, the cells were reincubated in nor-
moxic medium for 120 minutes. Conditioned medium was collected at
the end of each defined period and assayed by real-time polymerase chain
reaction for exported miRs.21
In VitroMembrane Type 1MatrixMetalloproteinase
Protein Modulation
Human LV myocardial fibroblasts (2 3 105 cells, n ¼ 3) were trans-
duced with 1 of 2 lentiviral vectors to overexpress miR-133a
(pMIRNA1-hsa-miR-133a-1) and for knockdown of miR-133a (pmiR-
Zip-hsa-miR-133a-1; both System Biosciences, Mountain View, Calif).
Five days after transduction, the fibroblasts were collected for determina-
tion of MT1-MMP protein levels.
Data Analysis
LV regional function and hemodynamics were compared between
groups by analysis of variance (ANOVA). Interstitial MT1-MMP activityery c January 2013
FIGURE 1. A, Regional myocardial contractile function. Time-
dependent rPRSW was determined in the remote (solid dot) and I/R
(open triangle) regions. A time- and region-dependent difference was
=
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steady-state values (steady-state set to 0). The integrated optical density
values for pSmad2, Smad2, and MT1-MMP were expressed as a percent
of controls and compared using a 1-sample t test. Levels of miRs and
mRNA expression levels were normalized to 18S or Caenorhabditis ele-
gans miR-39 values, as appropriate, and compared as a fold change from
control values by the DDCt method.22 Post hoc mean separation after
each ANOVAwas performed using Bonferroni-adjusted pairwise compar-
isons. Statistical analyses were performed using STATA statistical software
(StataCorp, College Station, Tex). Results are presented as the mean 
standard error of the mean.
RESULTS
LV function and hemodynamics at steady state and with
I/R are summarized in Table E1. Although heart rate in-
creased during reperfusion,1,2 LV peak systolic and mean
arterial pressures remained unchanged with I/R. This
suggests that the I/R protocol did not cause significant
hemodynamic compromise. However, regional segmental
shortening and rPRSW decreased in the I/R region with
ischemia and remained decreased during reperfusion
(Table E1 and Figure 1, A, respectively). Interstitial MT1-
MMP activity increased over time in both the I/R and
remote regions (Figure 1, B). However, interstitial MT1-
MMP–mediated LTBP-1 substrate hydrolysis increased
only within the I/R region (Figure 1, C).
Total Smad2 abundance increased in the I/R region after
I/R (Figure 2, A). A small increase in pSMAD2 was mea-
sured in the remote region, whereas a robust increase was
observed in the I/R region after I/R (P<.05 vs referent con-
trol) (Figure 2, A).
Myocardial mRNA levels of essential ECM-modifying
genes after I/R injury are shown in Figure 2, B. Relative
mRNA levels of MT1-MMP, MMP-9, LTBP-1, TGF-bR1,
and COL1A1 were increased within the I/R region, whereas
LTBP-1, TGF-bR1, and MT1-MMP mRNA levels were in-
creased in the remote region.
With ischemia, interstitial miR-133a levels decreased in
the both the I/R region and the remote region (Figure 3,
A, top and bottom). With reperfusion, interstitial miR-
133a levels returned to steady state within the I/R region
and remained decreased in the remote region. Interstitial
miR-29a levels remained unchanged in either region with
I/R (Figure 3, B, top and bottom). At the completion of
I/R, total myocardial miR-133a and miR-29a levels were
similar in the remote region, I/R region, and referentobserved (ANOVA; F ¼ 3.82 and F ¼ 27.74, respectively; P< .01). B,
MT1-MMP–specific fluorogenic peptide hydrolysis. A time- and region-
dependent difference was observed (ANOVA; F ¼ 9.50 and F ¼ 3.33,
respectively; P < .05). C, LTBP-1 substrate hydrolysis. A region-
dependent difference was observed (ANOVA, F ¼ 10.20, P<.05). *P<
.05 versus steady state. I/R, Ischemia–reperfusion; rPRSW, regional pre-
load recruitable stroke work; MT1-MMP, membrane type 1 matrix metal-
loproteinase; LTBP-1, latent transforming growth factor binding protein 1.
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FIGURE 2. Activation of TGF-b signaling pathway. A, Immunoblotting total Smad2 and pSmad2 in the remote region, I/R region, and controls (n ¼ 5).
*P<.05 versus control. zP<.05 versus remote region. B,Myocardial mRNA levels forMMP9,MT1-MMP, LTBP1, TGF-bR1, and COL1A1 (type I collagen)
in the remote region, I/R region, and controls. A region-dependent difference was observed (ANOVA; F ¼ 4.45, F ¼ 14.37, F ¼ 14.62, F ¼ 9.69, F ¼ 6.48,
respectively; all P<.05). *P<.05 versus control. IR, Ischemia–reperfusion; LTBP1, latent transforming growth factor binding protein 1;MMP9, matrix metal-
loproteinase 9;MT1-MMP,membrane type1matrixmetalloproteinase;pSMAD2, phosphorylatedSmad2;TGF-bR1, transforminggrowth factor beta receptor 1.
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spectively, P¼ .50;DDCt; miR-29a 1.12 0.51 and 1.18
0.62, respectively, P ¼ .78). With simulated I/R, levels of
miR-133a in the conditioned medium decreased with hyp-
oxia (P ¼ .047) and returned to steady state after reperfu-
sion (Figure 4, A).
In normal human LV fibroblasts, overexpression of miR-
133a caused a reduction in MT1-MMP protein levels270 The Journal of Thoracic and Cardiovascular Surg(Figure 4, B). Conversely, knockdown of miR-133a by
anti–miR-133a caused an increase in MT1-MMP protein
abundance.
DISCUSSION
Myocardial I/R can elicit a number of cellular and extra-
cellular events, including contractile dysfunction, localized
release of bioactive molecules, and induction of proteolyticery c January 2013
FIGURE 3. Interstitial miR levels. Interstitial levels of miR-133a and miR-29awere measured at steady state (gray), ischemia, and after reperfusion for the
I/R (white) and remote (black) regions. Top: absolute values. Bottom: Data are depicted as a percent change from steady state. A, Interstitial miR-133a. A
time-dependent difference was observed (steady-state miR-133a ¼ 3.233 103  1.15 3 103; ANOVA; F ¼ 3.50; P<.05). B, Interstitial miR-29a. No
change with I/R was observed (ANOVA, F ¼ 0.39, P<.68). *P<.05 versus steady state. zP<.05 versus ischemia. miR, MicroRNA.
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dance and activity.1,2 The miRs are a major determinant
of post-transcriptional regulation; certain miRs, such as
miR-133a and miR-29a, have been identified as important
mediators in ECM remodeling in the setting of I/R.8-10
Accordingly, this study tested the hypothesis that changes
in miR-133a regulation occur with acute myocardial I/R in-
jury, which contributes to time- and region-dependent
changes in MT1-MMP activity processing of MT1-MMP
substrates. The significant findings of the present study
are as follows: (1) The contractile deficit that occurred
with I/R was associated with increased MT1-MMP activity
in both the remote and I/R regions and increased hydrolysis
of the MT1-MMP substrate, LTBP-1, in only the I/R region.
Concomitantly, there were differential and dynamic
changes in interstitial levels of miR-133a without a change
in the total myocardial pool of miR-133a during I/R. (2)
Simulated I/R in myocardial fibroblasts recapitulated the
in vivo changes in miR-133a levels, suggesting a direct
role for I/R in the exportation of miR-133a. (3) miR-133a
transduction in myocardial fibroblasts resulted in a decrease
in MT1-MMP protein levels. (4) There was an acuteThe Journal of Thoracic and Caactivation of the TGF-b signaling pathway, components of
which include many targets of miR-133a. Therefore, these
findings suggest that changes in miR-133a levels during
acute I/R may potentiate long-term sequelae of TGF-b sig-
naling with respect to myocardial fibrosis and remodeling.
Thus, modulation of miR-133a represents a potentially
novel molecular target for regulating a cascade of TGF-b–
mediated profibrotic events after I/R.
Coronary revascularization after acute coronary syn-
drome is accompanied by I/R injury, which can result in re-
gional contractile dysfunction that gives rise to altered
stress/strain patterns during the cardiac cycle, as well as
the acute elaboration of a number of bioactivemolecules.2,23
These multifactorial changes lead to LV remodeling,
characterized by LV dilation and alterations in the content
and composition of the myocardial ECM.1,23,24 In the
present study, regional contractile dysfunction occurred
with I/R within the I/R region and transiently in the
remote region. The finding of persistent contractile
dysfunction despite reperfusion within the I/R region and
activation of a key proteolytic pathway mediated by MT1-
MMP is consistent with past studies.1,2,23 The presentrdiovascular Surgery c Volume 145, Number 1 271
FIGURE 4. In vitro studies. A, Levels of miR-133a in conditioned me-
dium from porcine LV fibroblast cultures (n¼ 3) under normoxia, hypoxia,
and reoxygenation as a function of normoxia levels. B, MT1-MMP protein
abundance in normal human LV fibroblast cultures (n ¼ 3) 5 days after
transductionwithmiR-133a or anti-miR-133a as a percent change from ref-
erent control values. *P<.05 versus steady state. zP<.05 versus ischemia.
miR, MicroRNA; MT1-MMP, membrane type 1 matrix metalloproteinase.
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upstream regulators and downstream effectors of altered
MT1-MMP activity are induced acutely with I/R. Specifi-
cally, processing of proteins that contribute to fibrosis
(LTBP-1 and TGF-b) and changes in interstitial miR content
was altered in the setting of I/R. However, it must be recog-
nized that alterations in loading conditions also may have
served as a stimulus for increased MT1-MMP activity and
LTBP-1 substrate hydrolysis at the I/R region. First, changes
in mechanical loading can alter MT1-MMP induction.25-28
For instance, mechanical stretch of murine aortic rings
increased activation of the MT1-MMP gene promoter.27
Likewise, increased mechanical loading of papillary mus-
cles increased MT1-MMP expression.28 Second, changes
in mechanical loading can change the conformation of the
cell surface integrins, which in turn may induce a conforma-
tional change in LTBP-1 through its integrin binding site and
release of TGF-b.29 The source of acute changes in272 The Journal of Thoracic and Cardiovascular Surginterstitial MT1-MMP activity notwithstanding, the results
from the present study demonstrate that long-term sequelae
of I/R, with respect to changes in contractile function andLV
remodeling, are likely initiated by these molecular events in
the early I/R period.
The miRs, which are post-transcriptional regulatory mol-
ecules, contribute to modulation of ECM remodeling
through regulation of processes, which in turn, contribute
to fibrosis and ECM degradation.8-10 For example,
overexpression of miR-133a decreased collagen production
in cardiac fibroblasts.9 In mice with cardiac-restricted miR-
133a overexpression, myocardial fibrosis was attenuated in
the setting of pressure overload hypertrophy.10 Also, miR-
29a knockdown was associated with increased mRNA
expression of fibrillar collagen in mice and a reduction of
infarct size in rats.8,30 An association between miR-133a
and several MMPs has been described in the setting of he-
matologic and cardiovascular diseases.30-35 For example,
a down-regulation of miR-133a was associated with in-
creased plasma levels of several MMP types in patients.35
With the development of ischemic heart disease, past stud-
ies have reported a decrease in miR-133a and an increase in
MT1-MMP protein abundance.1,31,34 Taken together, the
findings from these past studies and results from mapping
of a binding site for miR-133a on the MT1-MMP
transcript formed the rationale for examining the post-
transcriptional regulation of MT1-MMP by miR-133a in
the context of myocardial I/R injury. The present study
builds on these past reports by demonstrating that
myocardial fibroblasts synthesize and release miR-133a
and that changes in miR-133a levels can modulate MT1-
MMP protein abundance. Specifically, MT1-MMP abun-
dance was reduced after miR-133a overexpression in LV
fibroblasts, and conversely, MT1-MMP abundance in-
creased after LV fibroblasts were transduced with anti-
miR-133a. Together, these findings suggest a role for
miR-133a–mediated regulation of MT1-MMP abundance
(Figure 5) in the context of myocardial I/R.
Past in vitro studies have reported that miRs may be im-
ported/exported from cells,21 and a recent study reported
changes in total miR-133a levels in a rodent model of
I/R.36Building on these past findings, the present study dem-
onstrated that a quantifiable pool of miR-133a and miR-29a
was present in themyocardial interstitium. In addition, inter-
stitial miR-133a levels changed while the total myocardial
pool of miR-133a remained unaltered, suggesting that miR
exportation is regulatedwith I/R (Figure 5). Of note, intersti-
tial levels of miR-29a remained unchanged in the setting of
I/R, suggesting that miR-133a export is selective and I/R
specific. To examine this further, primary porcine LV fibro-
blasts were exposed to a simulated I/R protocol, and miR-
133a within the conditioned media decreased with hypoxia
and returned to steady-state levels with reoxygenation, in
concordance with the in vivo microdialysis findings.ery c January 2013
FIGURE 5. Working hypothesis regarding MT1-MMP activation and
changes in interstitial miR-133a with I/R. A, At steady state, MT1-MMP
mRNA is translated and ultimately transported to the membrane, yielding
a competent transmembrane protease. The present study identified a mea-
surable amount of miR-133a exportation into the myocardial interstitial
space, and MT1-MMP protein abundance can be regulated by miR-133a.
B,With acute ischemia, interstitialMT1-MMPactivity increases, likely be-
cause of increased trafficking to the membrane.1 Interstitial miR-133a
levels decreased, suggesting decreased exportation and increased intracel-
lular concentrations, where post-transcriptional regulation of its targets can
occur. C, With subsequent reperfusion, interstitial MT1-MMP activity re-
mained increasedwhile interstitial miR-133a returned to steady-state levels
within the I/R region, but exportation was not restored in the remote region.
Therefore, increased miR-133a exportation within the I/R region during re-
perfusion (ie, a decrease in the intracellular pool of miR-133a) would
relieve translational repression of miR-133a targets, including those in-
volved with the TGF-b signaling pathway. miR, MicroRNA; MT1-MMP,
membrane type 1 matrix metalloproteinase.
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tial and dynamic changes in extracellular miR content occur
in the setting of acute myocardial I/R.
It is important to note that miRs or closely related miR
families can target multiple mRNA transcripts involved in
common biological signaling cascades.37 For example, in
silico mapping studies of miR-133a have demonstrated sev-
eral putative targets involved in both ECMdegradation, such
as MMP-9 and MT1-MMP, and TGF-b–mediated fibrosis,
such as MT1-MMP, LTBP-1, COL1A1, and TGF-bR1. In
animal and clinical studies, an abundance of several
MMPs is generally increased with myocardial ischemia,
specifically MMP-9 and MT1-MMP.1,2,38 Although
changes in levels of bothMMP-9 andMT1-MMP are gener-
ally associated with inflammatory cell infiltration, both can
be produced by endogenous cells resident in the myocar-
dium and are involved in a number of proteolytic events
within the ECM.1-4,6,14,24 For example, MT1-MMP is
a membrane-bound MMP fundamental in activating
MMP-2 at the cell surface,5 and previous large animal stud-
ies have measured increased MT1-MMP with I/R injury.1,2
MT1-MMP also is involved in pericellular proteolysis and
the release of ECMgrowth factors from sequestration sites.4
In the present study, interstitial MT1-MMP activity was in-
creased in both the I/R and the remote regions. In a past study
that examined the effects of an antecedent MI that was fol-
lowed by acute I/R injury at the site remote from the original
MI, interstitial MT1-MMP activity within the remote myo-
cardial region remained unaltered for the duration of the I/
R period.2 In contrast, a small, but significant, increase in
MT1-MMP activity within the remote region during the I/
R period was observed in the present study. However, it
must be recognized that there are at least 2 differences
with respect to the experimental design between these 2
studies: First, the coronary artery bed perfusing the ‘‘re-
mote’’ myocardial region was different between the 2 stud-
ies. Specifically, the remote region was perfused by the left
anterior descending coronary artery in the present study and
through the circumflex arterial system in the past study.2 A
second, and perhaps more important, difference was the
time that ischemia was maintained. In the past study, ische-
mia was maintained for 60 minutes as opposed to the 90-
minute ischemic period in the present study.2 Although
this remains speculative, it is possible that the increase in is-
chemic time may have been sufficient to manifest in detect-
able changes in MT1-MMP activity within the remote
myocardial region. Indeed, long-term ischemia (ie, myocar-
dial infarction, as demonstrated in the same past study) was
associated with increased MT1-MMP activity in the region
remote from the MI.2 Therefore, the difference with respect
to induction ofMT1-MMP activity within the remote region
between the 2 studies may have been due to regional differ-
ences, as well as the time for which ischemia was main-
tained. Nevertheless, the present study demonstrated thatrdiovascular Surgery c Volume 145, Number 1 273
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increased, suggesting that acute induction of pathways con-
tributing to ECMproteolysis accompanies I/R. In vitro stud-
ies have provided evidence for MT1-MMP–mediated
proteolysis of LTBP-1, resulting in the release of TGF and
increased activation of profibrotic pathways.3,14 In mice
with cardiac-restricted overexpression of MT1-MMP, en-
hanced proteolytic processing of LTBP-1 was reported and
associatedwith elevatedTGF-b–mediated Smad2 activation
and increased myocardial fibrosis.3 A novel finding of the
present study was that MT1-MMP–mediated LTBP-1 sub-
strate proteolysis increased only in the I/R region. This
region-dependent MT1-MMP–mediated LTBP-1 substrate
proteolysis could set the stage for increased TGF-b signaling
within the I/R region. Consequently, protein and mRNA
levels of components in the TGF-b signaling pathway
were increased within the I/R region. Specifically, the abun-
dance and phosphorylation of Smad2 (pSmad2) were in-
creased in the I/R region concomitant with increased
mRNA expression of LTBP-1, TGF-bR1, and COL1A1.
Therefore, these results suggest that an acute, region-
dependent activation of TGF-b signaling and transcriptional
induction of profibrotic molecules occurred with I/R and
may promote fibrosis through the subsequent production
of ECMproteins. For example, in a pigmodel of myocardial
I/R, Barallobre-Barreiro and colleagues39 reported an in-
creased abundance of fibrillar collagen within the I/R region
at 15 and 60 days after the initial ischemic injury. Moreover,
previous studies have demonstrated that miR-133a can play
a regulatory role in the determination of collagen content
and connective tissue growth factor abundance, 2 compo-
nents that are important in myocardial fibrosis.9,10 The
present study demonstrated that interstitial signaling in
response to I/R activates both proteolytic and profibrotic
pathways, which are initiated at the time of the acute I/R
event and can potentiate LV remodeling over time.
Specifically, interstitial miR-133a decreased within both
the remote and I/R regions with ischemia, suggesting main-
tenance/increase of intracellular miR-133a, which could at-
tenuate translation of MT1-MMP and the components of
the TGF-b signaling pathway.9,10 With reperfusion,
extracellular miR-133a increased from ischemia to reperfu-
sion, suggesting a restoration of miR-133a export (or de-
crease in intracellular miR-133a) in the I/R region, but not
in the remote region (Figure 5). These findings suggest a po-
tential loss of miR-133a–mediated regulation of remodeling
processes within the I/R region. Therefore, it is likely that
the transient changes in miR expression during the I/R pe-
riod, as observed in the present study, set into motion a se-
quence of events that trigger changes in the abundance/
activity of proteins and activation of signaling cascades
that result in a fibrotic response. However, the present study
was focused on determining whether changes in miR abun-
dance could be detected within the myocardial interstitium274 The Journal of Thoracic and Cardiovascular Surgduring the acute phase of I/R, and not on long-term evalua-
tion of interstitial miR-133a and its downstream targets.
Therefore, future studies would be required to determine
the effect of the changes in miR-133a levels that occurred
with acute I/R on the abundance of myocardial proteins in
the ischemic and remote myocardial regions when studied
over longer (days/months) reperfusion periods.
The present study is not without limitations. It must be
recognized that miR-133a may bind to gene sequences for
a number of proteins, including those for MMP-9, MT1-
MMP, LTBP-1, TGF-bR1, TGF-b, and connective tissue
growth factor.11-13 Conversely, translation of these
proteins also may be regulated by a number of other
miRs.37 A number of cell types within the myocardium, in-
cluding myocytes and fibroblasts, are likely sources of miR-
133a.9,10,36,40 The rationale for examining the role of
myocardial fibroblasts with respect to changes in MT1-
MMP and miR-133a with I/R was 2-fold: First, fibroblasts
are the most numerous cell type within the myocardium
and contribute to myocardial remodeling through the syn-
thesis and release of MMPs, tissue inhibitors of matrix met-
alloproteases, and components of the ECM.41,42 Second, the
region of a myocardial infarct is often densely populated
with fibroblasts because of loss of myocytes secondary to
ischemic injury.43 The in vitro studies using simulated
hypoxia-reoxygenation in isolated myocardial fibroblasts
recapitulated the in vivo findings of I/R with respect to
changes inmiR-133a levels. This finding suggests that myo-
cardial fibroblasts contributed, at least in part, to changes in
interstitial levels of miR-133a with I/R. Finally, on the basis
of the finding that no differences in the total pool of miR
levels were noted among the remote region, I/R region,
and control myocardium, changes in interstitial miR-133a
levels likely reflected changes in intracellular miR-133a
levels. However, whether changes in interstitial miR levels
occurred because of changes in viability of cells in the I/R
region was not determined.
CONCLUSIONS
The findings of the present study demonstrated
I/R-dependent changes in MT1-MMP activity and TGF-b
signaling. These changes coincided with dynamic alter-
ations in miR-133a exportation into the myocardial intersti-
tium and may identify miR-133a as a novel target for
modulating the long-term sequelae that develop after a clin-
ically relevant I/R event.
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Dr Paul W. M. Fedak (Calgary, Alberta, Canada). There is
clear clinical evidence that even with early and successful reperfu-
sion after coronary occlusion, patients will undergo progressive
cardiac remodeling that can lead to heart failure. The key molec-
ular and cellular changes that occur after reperfusion are not
well known. It gives us a window of opportunity where we could
potentially treat patients early during or after reperfusion to pre-
vent maladaptive signals from happening, but we need to under-
stand them better. Your work is important because it leads us inrdiovascular Surgery c Volume 145, Number 1 275
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ing with those molecular and cellular changes.
What is unique and important is that you have been able to sep-
arate out region- and time-specific changes in a preclinical relevant
animal model. What is really important is that you are able to sep-
arate ECM interstitial signaling from the cellular changes. It is dif-
ficult to present that complexity of data in such a short period of
time, and you did a great job. I have a couple of questions for you.
You have designed your experiment to look at mechanistic data
and tried to tease out time- and region-specific changes and corre-
late those events. I note with your data you are trying to correlate
MT1-MMP activity and LTB processing, but in the remote area
during reperfusion you observed the highest levels of the MMP ac-
tively, but you didn’t observe the similar changes in the LTB pro-
cessing. Does that refute your hypothesis?
Dr Eckhouse. I believe the differences seen in MT1-MMP and
LTBP-1 activity with microdialysis actually support our
hypothesis.
First, in examining MT1-MMP activity with microdialysis dur-
ing the I/R protocol, there are several possible reasons that could
lead to this increased MT1-MMP activity in the remote region.
Previous studies from other laboratories have determined that
a phosphorylation event occurring at the C-terminus of MT1-
MMP can lead to a substrate specificity and directed localization
within a cell membrane. From these findings, our research group
hypothesizes that post-translational modifications of MT1-MMP
in vivo are promoting increased cleavage of the MT1-MMP fluo-
rogenic peptide in a region-dependent manner.
An important question to consider is how are the MT1-MMP
and LTBP-1 substrates different? The peptide sequences of each
substrate are different. The MT1-MMP fluorogenic peptide is
a synthetic amino acid sequence that is hydrolyzed specifically
by MT1-MMP in vitro and in vivo. Previous validation studies
confirmed that the amino acid sequence is specific for MT1-
MMP over other MMPs. The LTBP-1 fluorogenic peptide repre-
sents an endogenous substrate sequence that is hydrolyzed by
MT1-MMP. Previous in vivo studies have determined that with
overexpression of MT1-MMP, there is a decrease in full-length
LTBP-1 and an increase in the low-molecular-weight split prod-
ucts of LTBP-1 after MT1-MMP–mediated hydrolysis. Therefore,
MT1-MMP differentially processes the 2 synthetic peptides.
The cleavage of the LTBP-1 fluorogenic peptide was specific to
the I/R region, which is supported by the increase in the activation
of the TGF-ß profibrotic pathway as measured by pSmad2 in the
I/R region when compared with the remote region. Although not
in the presentation, gene expression of collagen 1A1 by quantita-
tive PCR was increased, which further suggests increased acute
activation of the TGF-ß profibrotic pathway within the I/R region
that was not measured within the remote region, as demonstrated
by no change in collagen 1A1 gene expression and a small increase
in pSmad2 protein abundance when compared with the referent
control.
Dr Fedak. Can you speculate what the triggers could be here?
Could wall stress be the key trigger, and if so, can you think of any-
thing we can do from a surgical point of view early after
reperfusion?
Dr Eckhouse. Wall stress has been demonstrated to be an im-
portant mechanism in activating MT1-MMP. We have seen this276 The Journal of Thoracic and Cardiovascular Surgin a recent murine model of pressure overload hypertrophy from
our laboratory published by Dr Zile and in in vitro aortic wall stress
studies.
The alteration in stress–strain patterns due to an acute I/R event
is causing an increase in MT1-MMP activation. Therefore, de-
creasing wall stress due to I/R remains important.
For a future surgical technique, it will be important to improve
stress–strain patterns. Although this may be more relevant to
a chronic infarction, improving the thickness of the affected myo-
cardium within the I/R injury region by injections of polymers or
other method is currently under investigation. However, there is
a lot of area for creativity.
Dr Fedak. Thank you.
Dr Joseph D. Schmoker (Burlington, Vt). To follow up on
Paul’s question about regional issues, there is a mechanism for un-
coupling of TGF-ß via mechanical transduction through the integ-
rin network, I believe. I was wondering if you came across that
mechanism and if that could serve as an explanation for why
you are seeing this only in the region of I/R?
Dr Eckhouse. I haven’t come across that mechanism specifi-
cally within this study, but one of my predecessors in the labora-
tory, Dr Ruddy, looked at the TGF-ß pathway within in vitro
studies of aortic wall stress. We are currently investigating in-
creased TGF-ß activation secondary to increased aortic wall stress
in models of aortic aneurysms. However, I haven’t looked at that
within the I/R myocardial model, but that is definitely an area to
look at.
Dr Schmoker. My other question relates to miR-133a, which
has been used as a biomarker in clinical trials. Could it be that
the interstitial levels you are measuring are simply secondary to
cell injury or death secondary to reperfusion? Have you looked
at that? In other words, do you have histology on your I/R region?
DrEckhouse. I don’t have histology data to present.We did cell
culture studies using primary porcine fibroblasts undergoing sim-
ulated in vitro I/R, and what we found when we measured miR-
133a within the conditioned media is consistent with our in vivo
evidence. When it comes to cell death, previous studies using
that same I/R model did not show increased cardiomyocyte death,
and we didn’t have increased fibroblast cell death with our simu-
lated hypoxia reoxygenation model.
Concurrently, with potential cell death within the I/R region, I
would have expected miR-133a extracellularly to increase more
with apoptosis and cell death and spillage of the intracellular
miR-133a into the interstitial space. However, with I/R within
that I/R region, we actually see a decrease during the ischemic
time of miR-133a.
Dr Schmoker. Right, but I think it is in the reperfusion episode
where you are really going to get the cell injury or death.
One last point. Cardiac myocytes are enriched with miR-133a,
but I don’t know the relative abundance of that miR-133a in fibro-
blasts. So I am wondering why you didn’t use cardiomyocytes in
your cell culture.
Dr Eckhouse. That is a study we are currently doing. We ha-
ven’t completed that study.We have been able to show a correlation
between MT1-MMP levels and miR-133a in myocardial fibro-
blasts. So we are able to demonstrate that miR-133a is within other
cells besides the cardiomyocytes, but we are specifically looking at
the cardiomyocytes now.ery c January 2013
Eckhouse et al Evolving Technology/Basic ScienceDr Stephen McKellar (Rochester, Minn). Elegant study and
model. Good presentation. You presented your I/R model here,
but have you looked at this or similar phenomena in an infarction
modelwith sampling in the infarct, border zones, and then distantly?
This is an elegant way of studying that region. Is that something you
could at least speculate on what you might find in that model?
Dr Eckhouse. A previous study evaluated MT1-MMP activity
within an infarction model with a subsequent I/R event 2 weeks af-
ter the infarction. MT1-MMP activity increased with infarction
and then subsequently increased even more after a subsequent
I/R event 2 weeks later. However, in regard to miR-133a, we
haven’t looked at the long-term effects of I/R on miR-133a levels,
but it is definitely something we are interested in.
Dr Thomas K.Waddell (Toronto, Ontario, Canada). My ques-
tion is along the lines of Dr Schmoker’s question about the release
of miR-133. You mentioned that the exportation was identified as
a mechanism of regulation, but on the 2 slides you showed, it was
clear that the Yaxis was different. So when you measured by PCR
the levels of the miR-133 in the interstitium versus the total, what
was the scale of that difference? I would put it to you that if theThe Journal of Thoracic and Catotal is a million, then what you are measuring in the interstitium
is 10. It probably doesn’t reflect regulation. What I would like you
to think about is perhaps it is a mechanism of communication—the
exportation of miR-133 allows that to be diffused outward. If that
is the case, youmight actually see increasing penumbra of decreas-
ing miR-133 levels. So you may want to look at your remote area
a little bit as proximal and distant remote.
Dr Eckhouse.Wedidn’t look at proximal and distant remote re-
gions of the myocardium. That is an interesting point and defi-
nitely a suggestion we will take to the laboratory. Our data with
our miR exportation seem to fit nicely with our acute TGF-ß acti-
vation. In the remote region, we saw a decrease in the interstitial
miR-133a levels, and it remained decreased with reperfusion,
which in comparison with total myocardial pools leads us to be-
lieve that miR-133a remains elevated intracellularly. Thus, miR-
133a can inhibit or attenuate the TGF-ß profibrotic pathway within
the remote region. Within the I/R region, the extracellular increase
in miR-133a may be associated with a intracellular decrease of
miR-133a, which may then allow activation of the TGF-ß profi-
brotic signaling pathways and promote fibrosis over time.rdiovascular Surgery c Volume 145, Number 1 277
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SUPPLEMENTAL METHODS
Model of Ischemia–Reperfusion
Yorkshire pigs (n ¼ 12, 30-35 kg; Hambone Farms, Or-
angeburg, SC)weremaintained on anesthesia usingmorphine
sulfate (3 mg/kg/h intravenously; Elkins-Sinn, Cherry Hill,
NJ) and isoflurane (2%, 3 L/min O2; Baxter Healthcare
Corp, Deerfield, Ill), and mechanical ventilation was main-
tained to achieve stable arterial blood gases (pH 7.35-7.45,
PO2 300 torr, PCO2 45 torr). An arterial line was placed
in the right carotid artery for continuous blood pressure mon-
itoring, and a previously calibrated microtipped transducer
catheter (7.5F; Millar Instruments Inc, Houston, Tex) was
placed into the left ventricle through the left carotid artery. Af-
ter a sternotomy, loosened snares were placed around the first
2 branches of the circumflex coronary artery, OM1 and OM2,
which was defined as the I/R region. A pair of sonomicrome-
try crystals (2mm; Sonometrics, London,Canada)was placed
in this targeted I/R region, aswell as another pair of sonomicr-
ometry crystals positioned in the anterior apical left ventricle,
which was defined as the remote region. A pair of microdial-
ysis probes (20 kDA, outer diameter of probe shaft 0.77 mm;
CMA/Microdialysis, North Chelmsford, Mass) was placed in
parallel between the sonomicrometry crystals within the I/R
and remote regions, respectively. A vessel loop was placed
around the inferior vena cava for transient caval occlusions.
All animals were treated and cared for in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals (1996).
After instrumentation and a 30-minute equilibration
period, steady-state measurements were digitized for analy-
sis (PONEMAH; Data Sciences, St Paul, Minn), which
included heart rate, mean arterial pressure, LV peak systolic
and end-diastolic pressures, and regional fractional segmen-
tal shortening. This was followed by simultaneous pressure
dimension measurements that were recorded with transient
caval occlusions to calculate regional LV preload rPRSW.E1
After steady-state measurements, the snares were tightened
for 90 minutes (ischemia) and then released for 120 minutes
(reperfusion). LV function was measured at 30-minute inter-
vals throughout I/R during the entire data-collection period.
Microdialysis infusion and collection were performed as
described in a subsequent section. After the end of the I/R
protocol, the LV free wall was removed and quickly divided
into the I/R and remote regions.A portion of themyocardium
from each region was flash-frozen in a dry ice/ethanol slurry
for subsequent biochemical analysis. For the purposes of
comparison, non-I/R–exposed LV myocardium from refer-
ent control pigs (n¼ 5)was harvested in an identical manner.
Microdialysis and Fluorogenic Substrate
Measurements
Parallel microdialysis probes (20 kDA, OD of probe shaft
0.77 mm; CMA/Microdialysis) were placed within the I/R
and the remote regions, and infused (3 mL/min) with MT1-
MMP or LTBP-1–quenched fluorogenic peptide substrates.
The microdialysis system and MT1-MMP–specific fluoro-
genic substrate [60 mmol/L, MCA-Pro-Leu-Ala-Cys(p-
OMeBz)-Trp-Ala-Arg(Dpa)-NH2; Calbiochem, La Jolla,
Calif; cat. no. 444258] has been described and valida-
ted.E2-E4 To create a fluorogenic construct of LTBP-1 prote-
olysis mediated by MT1-MMP, the full-length sequence of
LTBP-1 was first examined to identify potential MT1-
MMP–specific binding/cleavage sites.E2-E4 From these in
silico studies, a specific sequence identified to contain an
MT1-MMP cleavage site was used to synthesize a quenched
fluorogenic peptide substrate (Dabcyl-Ala-Gly-Gly-Glu-
Asn-Try-Lys-Asp-EDANS; National Center for Biotechnol-
ogy Information; AA30290.1).E2-E4 Past in vitro studies
havedemonstrated that thisLTBP-1substrateyieldeda linear
fluorescent signal with increasing concentrations of re-
combinant MT1-MMP, which was extinguished with
MT1-MMP neutralizing antibody, MT1-MMP selective in-
hibitor, or a global MMP inhibitor.E4 In the present study,
60mmol/L of LTBP-1 substratewas infused into themyocar-
dial interstitium, and peptide hydrolysis wasmeasured using
the microdialysis system. All microdialysis tubing and dial-
ysate collected were protected from ambient light. Fluores-
cence in the dialysate from the hydrolyzed peptides was
measured at excitation/emission wavelength of 328 nm/
400 nm for the MT1-MMP substrate and 340 nm/405 nm
for the LTBP-1 substrate (FLUOstar Galaxy fluorescent mi-
croplate reader; BMG LABTECH Inc, Cary, NC).
Immunoblotting
For determination of pSmad2 and Smad2 within the myo-
cardium, tissue samples were sequentially extracted as
previously described.E1Briefly,myocardial sampleswere ho-
mogenized in extraction/homogenization buffer (buffer vol-
ume used is 1:6 w/v; containing 10 mmol/L cacodylic acid
pH 5.0, 0.15 mol/L NaCl, 20 mmol/L ZnCl, 1.5 mmol/L
NaN3, 0.01% Triton X-100 [v/v], a protease inhibitory cock-
tail [cat no. P8340; Sigma, St Louis, Mo]) and centrifuged
(800g, 10 minutes, 4C). The supernatant was removed, and
protein concentrations were determined by using a bicincho-
ninic acid protein assay (product 23225; Thermo Scientific,
Rockford, Ill). For these studies, immunoblotting was first
performed for pSmad2, and the membranes were stripped
and reprobed for total Smad2 (cat no. 3101, 5339, respec-
tively, 1:1000; Cell Signaling, Danvers, Mass). The immuno-
reactive signals were analyzed using densitometric methods
(Gel Pro Analyzer; Media Cybernetics Inc, Rockville, Md)
to obtain 2-dimensional integrated optical density values.
MicroRNA Isolation and Quantification
The extracted myocardial RNA (1 mg) was reverse tran-
scribed (iScript cDNA Synthesis Kit; Bio-Rad, Hercules,
Calif) and amplified with gene-specific primer/probe sets
(TaqMan Universal PCR Master Mix, catalog no.
277.e1 The Journal of Thoracic and Cardiovascular Surgery c January 2013
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4364321, Applied Biosystems, Foster City, Calif) using
real-time PCR (CFX96 real-time PCR detection system;
Bio-Rad). The specific primer/probe sets were synthesized
for porcine LTBP-1 (Integrated DNATechnologies [Coral-
ville, Iowa], custom sequence: forward 50-AGGCCG TA
CTGGCTCTTTACAACA-30 reverse 50-AGCCAGAGGC
GGACTACTACGC CAA-30 probe 50-/56FAM/TTGGTTG
CCGCTTTCCACCATTAG/3BHQ-1/-30) and TGF-bR1
(Integrated DNA Technologies, custom sequence: forward
50-AAAGCTACATAACCTAC GGCCC-30 reverse 50-ACT
GAATCCTTGCTCGTCTG-30 probe 50/56-FAM/TGC CG
TATT/Zen/TCCAACACTCTGGGT/31ABkFQ/30), and
those for MT1-MMP, MMP-9, type I collagen, and 18S
rRNA were obtained commercially (Catalog no.
Ss03394431_m1, Ss03392098_m1, Ss03373340_m1, and
Hs99999901_s1, respectively, Applied Biosystems). Nega-
tive controls were run to verify the absence of genomic
DNA contamination (reverse transcription control) and
the absence of overall DNA contamination in the PCR sys-
tem and working environment (template control).
Bioinformatics Analysis of MicroRNA-133a
In silico mapping of the 30-UTR of the human MT1-
MMP gene (TargeScan Human 5.1, www.targetscan.org)
identified a high-probability target for miR-133a context
score 0.17, PCt 0.34).E5-E8 Of note, the 8-mer seed se-
quence was perfectly replicated in the 30-UTR of the por-
cine MT1-MMP gene. Moreover, when the human and
porcine 30-UTRs of MT1-MMP are aligned (ClustalW2;
http://www.ebi.ac.uk/Tools/msa/clustalw2/), the miR-133
target nucleotide sequence matches with identity at 25 of
31 base pairs, suggesting that porcineMT1-MMPs also pos-
sess a high-fidelity target site for miR-133a. In similar fash-
ion, miR-133a putatively targets several other genes that
play an important role in the profibrotic response, including
MMP-9, LTBP-1, TGF-bR1, and type I collagen.E7,E9,E10
MicroRNA Isolation and Quantification
The microdialysate samples (100 mL) underwent miR
isolation from both the I/R and remote regions at steady
state, 90 minutes ischemia, and 20 minutes reperfusion
(miRVana PARIS miR Isolation Kit, Catalog no.
AM1556, Applied Biosystems). The conditioned media
samples (100 mL) collected after 120 minutes of normoxia,
90 minutes of hypoxia, and 120 minutes of reoxygenation
also underwent miR isolation (miRVana PARIS miR Isola-
tion Kit, catalog no. AM1556, Applied Biosystems). A
custom-made exogenous Caenorhabditis elegans miR-39
sequence (10 ng; cel-miR-39; Integrated DNA Technolo-
gies) was added to each sample of microdialysate and con-
ditioned medium to measure extraction efficiency.
The myocardial samples (30 mg) were homogenized
(TissueLyser; Qiagen, Valencia, Calif), and the total RNA
was extracted (RNeasy Fibrous Tissue Mini Kit; Catalog
no. 74704; Qiagen). Total RNA quality and quantity were
then assessed (Experion Automated Electrophoresis Sys-
tem and StdSens RNA Analysis Kit, catalog no. 700-
7103, Bio-Rad), and aliquots were frozen at 80C.
Isolated RNA from the microdialysate, conditioned me-
dia, and myocardial homogenate was reverse transcribed
(TaqManMicroRNAReverse TranscriptionKit; AppliedBi-
osystems) and preamplified (TaqMan PreAmp Master Mix;
Applied Biosystems). Specific miR expression (hsa-miR-
29a Assay ID 002112, hsa-miR-133a-1 Assay ID 002246;
TaqMan MicroRNA RT Kit 4366579; Applied Biosystems)
was analyzedwith real-time PCR (CFX96 real-time PCRde-
tection system;Bio-Rad) using a 2-step procedure: Initial de-
naturation for 10 minutes at 95Cwas followed by 40 cycles
of 15 seconds at 95C and 60 seconds at 60C.
Simulated Ischemia–Reperfusion in Porcine Left
Ventricular Fibroblasts
In light of the fact that past in vitro studies have identified
potential traffickingof specificmiRs,E11 the present study ex-
aminedwhether and towhat degree indices ofmiR trafficking
could be identified with I/R by using a porcine LV fibroblast
system of hypoxia and reoxygenation. Isolation of porcine
LV fibroblasts (n ¼ 3 independent cell lines from 3 separate
control pigs) was performed as previously described.E12 Fi-
broblasts were grown to confluence in complete fibroblast
growth medium (FGM) (catalog no. C23010; Promocell,
Heidelberg, Germany) containing 20% fetal bovine serum
(catalog no. 10082-147; Invitrogen, Carlsbad, Calif), fibro-
blast growth supplement (Promocell, catalog no. C39325),
amphotericin B (2.5 ng/mL, catalog no.C42040, Promocell),
and gentamicin (50 mg/mL, catalog no. C42060, Promocell),
and incubated under standard culture conditions (37C, 5%
CO2, 21% O2). For these studies, each independent cell
line was assayed in triplicate. Cells from each line were
plated onto three 60-mm dishes (300,000 cells/dish) and in-
cubated overnight in complete medium without antibiotics
or antifungals. The following day, the mediumwas aspirated
and the cells were washed (2 mL, fresh medium). The fibro-
blasts were then subjected to 120 minutes of normoxia in
FGM (2mL, 37C, 5%CO2, 21%O2). At the end of the nor-
moxia period, the medium was collected and centrifuged
(450g for 4 minutes) to remove any cellular material. The
dishes were then incubated in FGM that had been depleted
of all oxygen content (hypoxiamedium, 2mL). To ensure ad-
equate oxygen depletion of the hypoxia medium, complete
FGM was infused with 95% nitrogen, 5% CO2 for 30 min-
utes (at 37C) before the addition to the fibroblast cultures.
The dishes were then placed into microincubators (Radnoti
GlassTechnology,Monrovia,Calif)with circulating 95%ni-
trogen, 5% CO2 for 90 minutes (at 37
C). The media were
again collected and centrifuged to remove any cellular mate-
rial as before (450g for 4 minutes). Next, the same fibroblast
cultureswere subjected to reoxygenation by the readdition of
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normoxic FGM (2 mL) for 120 minutes (37C, 5% CO2,
21% O2). After reoxygenation, the conditioned media were
once again collected. All of the conditioned media samples
were stored at 80C until analysis.
In VitroMembrane Type 1MatrixMetalloproteinase
Protein Modulation
To examine the role of miR-133a in regulating protein
levels of MT1-MMP, tools for permanent overexpression
and inhibition were used. Accordingly, human LV myocar-
dial fibroblasts (2 3 105 cells) (n ¼ 3) were grown to 70%
confluence in sterile T-25 culture flasks (BD Falcon, Le
Pont De Claix, France). After 24 hours, fibroblasts were
transduced with 1 of 2 lentiviral vectors allowing for the de-
livery of an miR precursor to LV fibroblasts in culture with
a multiplicity of infection of 10 in a 13 concentration of
a transduction efficiency reagent, Transdux (System Biosci-
ences) in fibroblast basal media with added supplement mix
and 10% fetal bovine serum for 3 days. Overexpression of
miR-133a was accomplished with the use of the pMIRNA1-
has-miR-133a-1 lentivector (System Biosciences). For
knockdown of miR-133a levels, the anti-miR-133a lentivi-
ral vector construct (pmiRZip-has-miR-133a-1; System
Biosciences) will result in the production of single-
stranded anti-miRs that competitively bind to endogenous
miR-133a targets, inhibiting interaction with mRNA. Five
days after transduction, the fibroblasts were collected and
analyzed by immunoblotting for MT1-MMP (AB8221;
Millipore, Billerica, Mass). The immunoreactive signals
were analyzed using densitometric methods (Gel Pro Ana-
lyzer, Media Cybernetics Inc) to obtain 2-dimensional inte-
grated optical density values.
Computations and Data Analysis
Statistical analyses were performed using STATA statis-
tical software (StataCorp, College Station, Tex). LV re-
gional function and hemodynamics were compared
between groups by ANOVA (prcomp module, STATA).
Fluorescence values corresponding to the interstitial MT1-
MMP activity and MT1-MMP–mediated LTBP-1 substrate
hydrolysis were evaluated by ANOVA and expressed as
a percent change from steady-state values (steady state set
to zero). The integrated optical density values for pSmad2
and Smad2 were then computed as a percent of control
values (control values set to 100), and comparisons were
performed by using a 1-sample t test. For the myocardial
miR levels and mRNA levels of MT1-MMP, MMP-9,
LTBP-1, TGF-bR1, and COL1A1, Ct values were normal-
ized to 18S Ct values (miR-Ct–18S-Ct ¼ DCt) and then
converted to expression levels (miR expression
level ¼ 2(-DCt)).E13 Myocardial miR expression levels also
were compared with control values (fold change miR
expression ¼ 2-(DCt-control DCt)).E13 A t test was performed
comparing fold change in expression with control (set to
1.0). For interstitial miR levels, the Ct values were normal-
ized to C elegans miR-39 Ct values (miR-Ct – miR-
39-Ct ¼ DCt) and converted to expression levels (miR
expression level ¼ 2-(DCt)), as previously described.E13
Interstitial miR expression levels were first compared
between groups by ANOVA and then expressed as a percent
change from steady state. A t test was performed on the per-
cent change in interstitial miR expression (steady state set to
zero percent change). A t test was performed on the percent
change of referent control for MT1-MMP protein abun-
dance (steady state set to 100% change). For conditioned
medium miR levels, the Ct values were normalized to
C elegans miR-39 Ct values (miR Ct – miR-39 Ct ¼ DCt)
and then converted to expression levels (miR expression
level ¼ 2-(DCt)), as previously described.E13 A 1-way t test
was performed on the percent change in conditioned
medium miR expression (steady state set to 100% change).
Post hoc mean separation after each ANOVA was per-
formed using Bonferroni-adjusted pairwise comparisons.
Results are presented as the mean  standard error of the
mean.
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TABLE E1. Left ventricular function and hemodynamics during the ischemia–reperfusion protocol
Steady state
Ischemia (min) Reperfusion (min)
30 90 30 120
Heart rate (beats/min) 84  5 86  5 88  4 115  7*,y 115  7*,y
Mean arterial pressure (mm Hg) 82  2 80  3 82  3 78  3 80  4
LV peak systolic pressure (mm Hg) 95.6  2.0 92.7  3.5 96.2  3.5 89.0  3.8 96.1  4.2
LV end-diastolic pressure (mm Hg) 6.9  0.7 7.6  1.1 8.1  1.0 7.3  0.9 6.8  0.9
Segmental shortening (%)
I/R region 15.21  2.02 2.79  2.21* 2.94  1.75* 0.81  1.72* 3.11  2.32*
Remote region 13.38  1.30 13.08  1.54 12.66  1.39 8.91  1.13 9.81  1.15
Values represent mean  standard error of the mean; n ¼ 12. LV, Left ventricular; I/R, ischemia–reperfusion. *P<.05 versus steady state. yP<.05 versus 90 minutes ischemia.
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